Fracture risk assessment in osteoporosis management.

Osteoporosis--a chronic, debilitating disease--predisposes patients to fractures of the hip, spine, vertebrae, and other skeletal sites. For many years, measurement of bone mineral density (BMD) has been the primary method of determining patients' need for osteoporosis pharmacotherapy. Although BMD...

Descripción completa

Detalles Bibliográficos
Publicado en:American Journal for Nurse Practitioners Vol. 13; no. 9; pp. 36 - 40
Autor principal: Kessenich CR
Formato: pictorial tables/charts Journal Article
Publicado: NP Communications, LLC (New Jersey) Sep2009
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105323887&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 105323887
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        15221431
        1FR7
      jtl: American Journal for Nurse Practitioners
      issn: 15221431
      maglogo: N
    pubinfo:
      dt: Sep2009
      vid: 13
      iid: 9
      pid: 71233
      pub: NP Communications, LLC (New Jersey)
      place: Monroe Township, New Jersey
    artinfo:
      ui:
        105323887
        105323887
        2010436074
        105323887
      ppf: 36
      ppct: 4
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Fracture risk assessment in osteoporosis management.
      aug:
        au: Kessenich CR
      sug:
        subj:
          Clinical Assessment Tools
          Fractures Prevention and Control
          Osteoporosis Prevention and Control
          Risk Assessment
          Bone Density Evaluation
          Cost Benefit Analysis
          Information Resources
          World Wide Web
      ab: Osteoporosis--a chronic, debilitating disease--predisposes patients to fractures of the hip, spine, vertebrae, and other skeletal sites. For many years, measurement of bone mineral density (BMD) has been the primary method of determining patients' need for osteoporosis pharmacotherapy. Although BMD measurement remains the gold standard for diagnosing and monitoring patients with osteoporosis, this technology is not available to all patients and should not be used as the sole method of determining the need for osteoporosis treatment. To address the issue of fracture assessment, the World Health Organization convened an international panel of osteoporosis experts to develop a fracture risk assessment model, which is known as FRAX. The model has some limitations in terms of the data included and the populations used to derive the algorithms. Research is needed to determine the validity of this tool for patients in the United States. This article describes the FRAX model specifically in terms of its cost-effectiveness, benefits, and limitations, and discusses the implications for nurse practitioners caring for patients with osteoporosis.
      pubtype: Academic Journal
      doctype:
        pictorial
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N